Latest Period
Q4 2025
Security Snapshot
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) Institutional Ownership
CUSIP: 747324101
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
78
Shares (Excl. Options)
30,195,945
Price
$1.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- PYXS on Nasdaq
- Shares outstanding
- 62,130,557
- Price per share
- $1.70
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 30,195,945
- Total reported value
- $34,729,768
- % of total 13F portfolios
- 0%
- Share change
- -780,136
- Value change
- -$6,939,019
- Number of holders
- 78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 747324101.
- 78 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 78 to 38 between Q4 2025 and Q1 2026.
- Reported value moved from $34,729,768 to $16,199,573.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 78 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 747324101?
CUSIP 747324101 identifies PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 747324101:
Significant Owners of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sullivan Lara | 11% | +9.1% | $7,844,727 | +$955,040 | 7,543,007 | +14% | Lara Sullivan, M.D. | 31 Mar 2025 |
| Laurion Capital Management LP | 7.7% | $9,880,747 | 4,796,479 | Laurion Capital Management LP | 31 Dec 2025 | |||
| GordonMD Global Investments LP | 6.2% | $5,330,289 | 3,834,740 | GordonMD Global Investments LP | 14 Jul 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 4% | -26% | $2,587,602 | -$698,942 | 2,488,079 | -21% | Millennium Management LLC | 31 Mar 2025 |
| BlackRock, Inc. | 1.5% | -68% | $2,192,635 | -$5,718,934 | 926,805 | -72% | BlackRock, Inc. | 30 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | -73% | $1,497,185 | -$4,985,888 | 818,134 | -77% | Millennium Management LLC | 30 Sep 2025 |
| Ridgeback Capital Investments L.P. | 0.6% | $373,600 | 359,231 | Ridgeback Capital Investments L.P. | 31 Dec 2024 |
As of 31 Dec 2025, 78 institutional investors reported holding 30,195,945 shares of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS). This represents 49% of the company’s total 62,130,557 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) together control 46% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Pfizer Inc | 11% | 7,032,770 | 0% | 3.4% | $8,087,685 |
| Laurion Capital Management LP | 7.7% | 4,796,479 | +32% | 0.38% | $5,515,951 |
| GordonMD Global Investments LP | 6.6% | 4,121,870 | 0% | 3.4% | $4,740,151 |
| VANGUARD GROUP INC | 3.8% | 2,335,768 | +7.9% | 0% | $2,686,133 |
| Palo Alto Investors LP | 1.7% | 1,037,421 | 0% | 0.17% | $1,193,034 |
| 683 Capital Management, LLC | 1.4% | 891,910 | +70% | 0.09% | $1,025,697 |
| JANE STREET GROUP, LLC | 1.3% | 786,010 | +159% | 0% | $903,911 |
| BlackRock, Inc. | 1.3% | 784,077 | +15% | 0% | $901,689 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 743,107 | -8.9% | 0% | $854,573 |
| RENAISSANCE TECHNOLOGIES LLC | 1.2% | 728,380 | +26% | 0% | $837,637 |
| Atle Fund Management AB | 0.99% | 617,245 | 0.23% | $709,831 | |
| BANK OF AMERICA CORP /DE/ | 0.95% | 587,851 | -4.6% | 0% | $676,029 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 577,211 | +6% | 0% | $664,211 |
| Longaeva Partners L.P. | 0.81% | 503,214 | 0% | 0.07% | $578,696 |
| UBS Group AG | 0.63% | 392,766 | +5.1% | 0% | $451,681 |
| MARSHALL WACE, LLP | 0.63% | 389,764 | 0% | $448,229 | |
| Decheng Capital LLC | 0.53% | 326,810 | 0% | 0.05% | $375,832 |
| ExodusPoint Capital Management, LP | 0.51% | 317,769 | 0% | $365,434 | |
| XTX Topco Ltd | 0.47% | 289,033 | +1533% | 0.01% | $332,388 |
| CITADEL ADVISORS LLC | 0.39% | 243,589 | -28% | 0% | $280,127 |
| STATE STREET CORP | 0.39% | 241,637 | +20% | 0% | $277,883 |
| Point72 Asset Management, L.P. | 0.3% | 188,136 | 0% | $216,356 | |
| Graham Capital Management, L.P. | 0.3% | 183,942 | 0.01% | $211,533 | |
| Bank of New York Mellon Corp | 0.27% | 165,044 | 0% | 0% | $189,800 |
| Qube Research & Technologies Ltd | 0.23% | 145,813 | +373% | 0% | $167,685 |
Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 11,831,012 | $16,199,573 | -$737,583 | $1.46 | 38 |
| 2025 Q4 | 30,195,945 | $34,729,768 | -$6,939,019 | $1.15 | 78 |
| 2025 Q3 | 26,713,589 | $59,287,871 | +$123,860 | $2.22 | 72 |
| 2025 Q2 | 27,457,764 | $30,197,446 | -$2,879,012 | $1.10 | 74 |
| 2025 Q1 | 30,249,732 | $29,641,653 | -$2,654,672 | $0.98 | 88 |
| 2024 Q4 | 31,554,509 | $49,227,444 | -$20,797,470 | $1.56 | 97 |
| 2024 Q3 | 27,885,908 | $103,378,553 | -$998,440 | $3.67 | 91 |
| 2024 Q2 | 28,117,599 | $93,075,160 | +$16,220,879 | $3.31 | 78 |
| 2024 Q1 | 22,927,678 | $97,671,130 | +$61,948,310 | $4.26 | 69 |
| 2023 Q4 | 8,795,542 | $15,830,945 | +$874,420 | $1.80 | 50 |
| 2023 Q3 | 7,757,315 | $15,436,473 | -$3,354,663 | $1.99 | 49 |
| 2023 Q2 | 9,605,170 | $24,586,580 | -$3,344,692 | $2.56 | 46 |
| 2023 Q1 | 10,344,999 | $41,482,052 | -$20,570,227 | $4.01 | 46 |
| 2022 Q4 | 19,762,209 | $26,479,807 | -$1,331,635 | $1.34 | 31 |
| 2022 Q3 | 19,443,728 | $38,301,000 | -$1,468,358 | $1.97 | 35 |
| 2022 Q2 | 20,034,321 | $47,682,000 | -$658,113 | $2.38 | 37 |
| 2022 Q1 | 18,945,997 | $76,067,000 | -$5,559,229 | $4.04 | 44 |
| 2021 Q4 | 18,338,628 | $199,903,000 | +$199,792,959 | $10.97 | 51 |